Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (December 2019)
30 slides from Windtree Therapeutics's investor presentation, Dec 11, 2019
Slide 1: Investor Call Presentation
Investor Call Presentation December 11, 2019 WINDTREE THERAPEUTICS OTCQB: WINT
Slide 2: Forward-looking Statements
Forward-looking Statements To the extent that statements in this presentation are not strictly historical, including statements about the Company's clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agree
Slide 3: Windtree Therapeutics Highlights
Windtree Therapeutics Highlights = Late-stage pipeline of novel cardiovascular and pulmonary programs + Three clinical programs with phase 2 data and pre-clinical pipeline candidates in both cardiovascular and pulmonary indications = Lead program, istaroxime (Ista), is a -class SERCA2a activator bei
Slide 4: $26.4 Million Private Placement Overview
$26.4 Million Private Placement Overview = Private placement of 8.7 million shares of common stock at a per share purchase price equal to $3.02 (10% discount from the 30-day average closing price through November 29, 2019) for gross proceeds of $26.4 million + Proceeds include $2.95 millionin non-ca
Slide 5: Financial Position Update
Financial Position Update As of December 10, 2019 = Cash and cash equivalents of $24.5 million as of December 10, 2019 (net of $0.5 million in estimated transaction related fees) = $4.5 million of debt in a bank credit facility currently due in March 2020 * working with bank to extend maturity to Ju
Slide 6: Current Capital Summary
Current Capital Summary Common Stock 41,035,282 Warrants Series | ($4.03 exercise price; expiring December 2024) 4,375,002 AEROSURF Warrants (dividend warrants to legacy WINT shareholders; expiring February 2024) 2,963,167 December 2018 Private Placement - Series F ($3.68 exercise price ; expiring J
Slide 7: Windtree Therapeutics Portfolio
Windtree Therapeutics Portfolio Late-Stage Programs in Cardiovascular and Acute Pulmonary Cardiovascular Istaroxime for the Treatment of Acute Heart Failure + Pre-Clinical Oral, Heart Failure Candidates and Programs: Cv-IsT2 SERCA2a (Next Generation Dual {Selective Action) Action SERCA2a) Oral & i.v
Slide 8: Strategy for Value Creation
Strategy for Value Creation Planned Milestones * Three late-stage programs focused on significant markets with unmet needs * Multiple clinical and business milestones which have the potential to be catalysts * Highly-experienced management team conducting smart, rigorous execution and leveraging opp
Slide 9: Istaroxime
Istaroxime Dual Mechanism, SERCA2a Activator for the Treatment of Acute Heart Failure @ and Early Cardiogenic Shock
Slide 10: Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need
Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need = 6 million patients in the U.S. and over 18 million worldwide. The prevalence of HF is on the rise as is mortality #1 cause of hospitalizations in patients over 65 years old in the United States and Western Europe wit
Slide 11: Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need
Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need ™ Despite the need, there has not been a meaningful new therapeutic advancements in acute heart failure for decades = Current approaches to acutely improve cardiac function are associated with unwanted effects: ° Heart
Slide 12: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy = Novel, intravenous agent designed to improve systolic contraction and diastolic relaxation and fill function of the heart = Unique, dual mechanism of effect that has been shown to impact both systolic and diastolic dysfunction © Inhibition of the sodium-po
Slide 13: Istaroxime Development
Istaroxime Development Leveraging the Istaroxime Profile to Produce Positive Results Istaroxime is being developed with the objective to improve cardiac function without the unwanted side effects of existing therapies 6 studies with 3 doses in 280 patients: Phase 2a Phase 2b * Hospitalized with AHF;
Slide 14: Istaroxime Phase 2b Study - Summary
Istaroxime Phase 2b Study - Summary * A 24-hour infusion of istaroxime at doses of 0.5 and 1.0 g/kg/min was associated with significant improvements in diastolic and systolic cardiac function at 24 hours. * The primary endpoint, E/e' at 24 hours, was significantly (p<0.05) improved by both doses of
Slide 15: Istaroxime — Acute Heart Failure — Program Status
Istaroxime — Acute Heart Failure — Program Status 1. The Company has worked with top Heart Failure advisors and has had positive engagement and guidance from the FDA v_ The FDA granted Fast Track designation to the program in July 2019 2. The Company plans to transition istaroxime to phase 3-ready a
Slide 16: Early Cardiogenic Shock Treatment
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway ™ Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output " Cardiogenic shock is an area of ex
Slide 17: Istaroxime SBP Change from Baseline
Istaroxime SBP Change from Baseline to 6 or 24 Hours from the Phase 2a and 2b Dose Groups Istaroxime has the potential to improve blood pressure and organ perfusion in patients with AHF 20.0 2 18.0 £160 ww 14.0 a #120 © 100 § 80 § 38 & 6.0 8 = 40 a 5 20 0.0 2a Study 2b Study 2a Study 2b Study 2a Stu
Slide 18: Rationale for Istaroxime in Early Cardiogenic Shock
Rationale for Istaroxime in Early Cardiogenic Shock = Dose related changes in systolic blood pressure in the phase 2 clinical program suggest a meaningful increase in blood pressure may be achieved in early cardiogenic shock by istaroxime = Improving systolic and diastolic cardiac function without i
Slide 19: Novel Heart Failure Portfolio
Novel Heart Failure Portfolio- q Oral and IV SERCA2aq Activators for Chronic & Acute Heart Failure 2 Dual Mechanism SERCA2a Selective SERCA2Za Activators Activators = SERCA2a activators with Na*/K* ® Selective SERCA2a Activators devoid of pump inhibitory activities any Na*/K* pump inhibitory activit
Slide 20: AEROSURF
AEROSURF* Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System for the Treatment of RDS
Slide 21: Respiratory Distress Syndrome (RDS)
Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf
Slide 22: Windtree Technology Platform - AEROSURF
Windtree Technology Platform - AEROSURF® Proprietary Synthetic KL4 Surfactant Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLé surfactant (intratracheal instillate) ability to aerosolize KLs surfactant for RDS approved by the FDA Lyoph
Slide 23: AEROSURF - Potential to Impact the Clinical Course of RDS
AEROSURF® - Potential to Impact the Clinical Course of RDS Building Evidence From 350 Patients Studied Noninvasive RDS treatment AEROSURF® eau Respiratory Parameters Long-Term Outcomes Study results across each of these important parameters show evidence i) of the potential to impact the clinical co
Slide 24: AEROSURF Program Evolution and Strategy
AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach Program Evolution Program Strategy = The three phase 2a and 2b clinical trials have reproduced efficacy in reducing nCPAP failure and the need for intubation when dosed as intended and observed important positiv
Slide 25: Potential Drivers of AEROSURF Opportunity
Potential Drivers of AEROSURF® Opportunity eAbade AEROSURF® Potential (see appendix) #1 20-30% _— ff Price Market statedunmet _ reduction (but }Total = E i A q Xpansion need in RDS NCPAP failure is Hospital Cost) ” meaningful “Noninvasive Results in >40% Potential for Potential to bring surfactant d
Slide 26: Rostafuroxin
Rostafuroxin for genetically targeted resistant hypertension and renal impairment S@ winotree we =
Slide 27: Hypertension Market — A Unique, Genetically-Targeted Approach
Hypertension Market — A Unique, Genetically-Targeted Approach * Hypertension is a very large market with high unmet need * Over 1/3 of the adult population in the U.S. has hypertension and the majority of treated patients (50-85% globally) do not reach target for control. Well known that ethnicity c
Slide 28: Business Development Focus
Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 — Partner Model Heart Failure Portfolio Partner — Global Rosta Out-License - Global AEROSUR
Slide 29: Clinical and Business Strategy for Value Creation
Clinical and Business Strategy for Value Creation Deliver Milestones, Execute Transactions * Istaroxime: Study early cardiogenic shock to explore potential accelerated pathway for this indication. Complete Ista AHF phase 2 clinical program and develop strong phase 3 and partnership position. To crea
Slide 30: Windtree Therapeutics
Windtree Therapeutics
Windtree Therapeutics — Investor Presentation (December 2019) on 6ix